Objectives: The objective of this study was to explore the relationships between circulating uric acid and lipid levels and components of the metabolic syndrome (MetS) in Arab dyslipidemic patients, a group already at high coronary artery disease risk. Subjects and Methods: The medical records of 1,229 subjects (632 men, 597 women) referred for treatment of dyslipidemia and followed up for at least 12 months were reviewed. Serum levels of uric acid and lipids (total cholesterol, triglycerides, low-density lipoprotein, high-density lipoprotein) and other variables in the National Cholesterol Education Program ATP III criteria definition of MetS were assessed at initial presentation and every 4– 6 months, under specific lipid-lowering treatment (statins and/or fibrates), in each of the subjects. Their respective associations were explored by appropriate logistic regression techniques with control for confounding risk factors, including age, gender and body mass index. Results: 306 subjects (24.9%) of the study population were hyperuricemic; they were more likely to be men, obese and diabetic. Also the serum uric acid level (mean ± SD) was greater in men with MetS compared with men without (377.0 ± 98.0 vs. 361.6 ± 83.1 µmol/l, p < 0.05), an observation not reproduced in women. Uric acid levels had significant associations with the presence of fasting hyperglycemia, hypertension and large waist circumference (WC) in men, but only with large WC in women. With statin treatment, uric acid levels decreased by 10% within 1 year of treatment; with fibrates, uric acid levels remained unchanged or slightly increased. Conclusion: The data showed that hyperuricemia is common in dyslipidemic patients in Kuwait, where its important determinants are male sex, obesity, diabetes and statin treatment.

Keywords:
Urate, Metabolic syndrome, Dyslipidemia, Arabs, Insulin resistance, Coronary artery disease, Hydroxymethylglutaryl coenzyme A reductase inhibitor
1.
Villegas R, Xiang YB, Cai Q, Fazio S, Linton M, Li H, Elasy T, Zheng W, Shu XO: Prevalence and determinants of hyperuricemia in middle-aged, urban Chinese men. Metab Syndr Relat Disord 2010;8:263–270.
2.
Lohsoonthorn V, Dhanamun B, Williams MA: Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams. Arch Med Res 2006;37:883–889.
3.
Sturge RA, Scott JT, Kennedy AC, Hart DP, Buchanan WW: Serum uric acid in England and Scotland. Ann Rheum Dis 1977;36:420–427.
4.
Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL, Sharrett AR, Davis CE, Heiss G: Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 1996;45:699–706.
5.
Al-Arfaj A: Hyperuricemia in Saudi Arabia. Rheumatol Int 2001;20:61–64.
6.
Nagahama K, Iseki K, Inoue T, Touma T, Ikemiya Y, Takishita S: Hyperuricemia and cardiovascular risk factor clustering in a screened cohort in Okinawa, Japan. Hypertens Res 2004;27:227–233.
7.
Al-Isa A, Akanji AO, Thalib L: Prevalence of the metabolic syndrome among female Kuwaiti adolescents using two different criteria. Br J Nutr 2009;7:1–5.
8.
Sanisoglu SY, Oktenli C, Hasimi A, Yokusoglu M, Ugurlu M: Prevalence of metabolic syndrome-related disorders in a large adult population in Turkey. BMC Public Health 2006;6:92.
9.
Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–359.
10.
Liou TL, Lin MW, Hsiao LC, Tsai TT, Chan WL, Ho LT, Hwu CM: Is hyperuricemia another facet of the metabolic syndrome? J Chin Med Assoc 2006;69:104–109.
11.
Ogata N, Fujimori S, Oka Y, Kaneko K: Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids 2010;29:321–324.
12.
Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Milionis HJ, Mikhailidis DP; GREACE Study Collaborative Group: Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589–599.
13.
Al-Huthi MA, Raja’a YA, Al-Noami M, Abdul Rahman A: Prevalence of coronary risk factors, clinical presentation, and complications in acute coronary syndrome patients living at high vs low altitudes in Yemen. MedGenMed 2006;8:28.
14.
Qadan LR, Ahmed AA, Safar HA, Al-Bader MA, Ali AA: Prevalence of metabolic syndrome in patients with clinically advanced peripheral vascular disease. Angiology 2008;59:198–202.
15.
Warnick GR, Knopp RH, Fitzpatrick V, Branson L: Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints. Clin Chem 1990;36:15–19.
16.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2497.
17.
Akanji AO: Diabetic dyslipidaemia in Kuwait. Med Princ Pract 2002;11(suppl 2):47–55.
18.
Abdulle AM, Nagelkerke N, Abouchacra S, Obineche EN: Potential benefits of controlling coronary heart disease risk factors in the United Arab Emirates. Kidney Blood Press Res 2008;31:185–188.
19.
Meagher EA: Addressing cardiovascular disease in women: focus on dyslipidemia. J Am Board Fam Pract 2004;17:424–437.
20.
Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS: Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander? Metabolism 2006;55:1293–1301.
21.
Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G: The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008;392:1–7.
22.
Numata T, Miyatake N, Wada J, Makino H: Comparison of serum uric acid levels between Japanese with and without metabolic syndrome. Diabetes Res Clin Pract 2008;80:e1–e5.
23.
Hayden M, Tyagi S: Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus – the urate redox shuttle. Nutr Metab (Lond) 2004;1:10.
24.
Sumino H, Ichikawa S, Kanda T, Nakamura T, Sakamaki T: Reduction of serum uric acid by hormone replacement therapy in postmenopausal women with hyperuricaemia. Lancet 1999;354:650.
25.
Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M: Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005;11:4161–4175.
26.
Bonetti PO, Lerman LO, Napoli C, Lerman A: Statin effects beyond lipid lowering – are they clinically relevant? Eur Heart J 2003;24:225–248.
27.
Mcfarlane SI, Muniyappa R, Francisco R, Sowers JR: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451–1458.
28.
Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial – FAT). Cardiovasc Res 2001;52:290–298.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.